• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    10/14/22 1:44:03 PM ET
    $APDN
    $ATXI
    $IMRA
    $MRKR
    Other Consumer Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APDN alert in real time by email

    Gainers

    • Avenue Therapeutics (NASDAQ:ATXI) stock rose 38.8% to $3.37 during Friday's regular session. Trading volume for Avenue Therapeutics's stock is 49.0 million as of 13:30 EST. This is 1901.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.9 million.
    • Imara (NASDAQ:IMRA) shares rose 35.65% to $3.5. The current volume of 31.3 million shares is 1186.7% of Imara's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $92.0 million.
    • Marker Therapeutics (NASDAQ:MRKR) stock moved upwards by 22.58% to $0.38. As of 13:30 EST, this security is trading at a volume of 1.0 million shares, making up 57.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $31.7 million.
    • Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 17.42% to $0.77. The current volume of 3.3 million shares is 339.5% of Sunshine Biopharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $14.4 million.
    • Predictive Oncology (NASDAQ:POAI) stock increased by 16.28% to $0.35. Trading volume for Predictive Oncology's stock is 266.8K as of 13:30 EST. This is 130.5% of its average full-day volume over the last 100 days. The company's market cap stands at $27.8 million.
    • Reata Pharmaceuticals (NASDAQ:RETA) stock increased by 16.24% to $29.12. Trading volume for Reata Pharmaceuticals's stock is 3.0 million as of 13:30 EST. This is 388.1% of its average full-day volume over the last 100 days. The company's market cap stands at $1.0 billion.

    Losers

    • Novo Integrated Sciences (NASDAQ:NVOS) stock fell 54.6% to $0.34 during Friday's regular session. As of 13:30 EST, this security is trading at a volume of 2.2 million shares, making up 16564.7% of its average full-day volume over the last 100 days. The company's market cap stands at $10.5 million.
    • Minerva Surgical (NASDAQ:UTRS) stock fell 29.75% to $0.42. As of 13:30 EST, Minerva Surgical's stock is trading at a volume of 290.7K, which is 589.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.0 million.
    • Nutex Health (NASDAQ:NUTX) stock decreased by 17.26% to $0.79. Trading volume for Nutex Health's stock is 9.6 million as of 13:30 EST. This is 468.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $513.5 million.
    • Rani Therapeutics Hldgs (NASDAQ:RANI) shares declined by 17.11% to $7.17. As of 13:30 EST, this security is trading at a volume of 96.8K shares, making up 156.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $175.6 million.
    • Nuwellis (NASDAQ:NUWE) stock decreased by 14.16% to $0.28. As of 13:30 EST, this security is trading at a volume of 2.8 million shares, making up 87.3% of its average full-day volume over the last 100 days. The company's market cap stands at $3.0 million.
    • Applied DNA Sciences (NASDAQ:APDN) stock declined by 13.13% to $2.45. Trading volume for this security as of 13:30 EST is 2.7 million, which is 28.7% of its average full-day volume over the last 100 days. The company's market cap stands at $31.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN
    $ATXI
    $IMRA
    $MRKR

    CompanyDatePrice TargetRatingAnalyst
    Marker Therapeutics Inc.
    $MRKR
    3/5/2025$8.00Buy
    Canaccord Genuity
    Nutex Health Inc.
    $NUTX
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    Nutex Health Inc.
    $NUTX
    9/18/2024$45.00Buy
    Maxim Group
    Predictive Oncology Inc.
    $POAI
    8/19/2024$3.00Buy
    H.C. Wainwright
    Rani Therapeutics Holdings Inc.
    $RANI
    8/2/2024$17.00Outperform
    Oppenheimer
    Nuwellis Inc.
    $NUWE
    7/29/2024$17.00Buy
    ROTH MKM
    Rani Therapeutics Holdings Inc.
    $RANI
    6/14/2024$15.00Buy
    Maxim Group
    Rani Therapeutics Holdings Inc.
    $RANI
    6/13/2024$10.00Buy
    Rodman & Renshaw
    More analyst ratings

    $APDN
    $ATXI
    $IMRA
    $MRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Mcdonald David

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    3/2/26 4:08:18 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Schultz Carisa

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    2/12/26 4:15:30 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Field Katharyn

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    2/11/26 3:35:38 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APDN
    $ATXI
    $IMRA
    $MRKR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SKYCLARYS issued to REATA PHARMACEUTICALS INC

    Submission status for REATA PHARMACEUTICALS INC's drug SKYCLARYS (ORIG-1) with active ingredient OMAVELOXOLONE has changed to 'Approval' on 02/28/2023. Application Category: NDA, Application Number: 216718, Application Classification: Type 1 - New Molecular Entity

    2/28/23 5:14:09 PM ET
    $RETA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $ATXI
    $IMRA
    $MRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Bates Jon Christian bought $102,532 worth of shares (750 units at $136.71), increasing direct ownership by 15% to 5,638 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    11/28/25 2:11:24 PM ET
    $NUTX
    Real Estate

    Director Imran Mir A bought $1,260,417 worth of shares (2,083,334 units at $0.60) (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    10/27/25 7:24:25 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    4/14/25 4:30:48 PM ET
    $NUTX
    Real Estate

    $APDN
    $ATXI
    $IMRA
    $MRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Marker International with a new price target

    Canaccord Genuity initiated coverage of Marker International with a rating of Buy and set a new price target of $8.00

    3/5/25 7:37:58 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group reiterated coverage on Nutex Health with a new price target

    Maxim Group reiterated coverage of Nutex Health with a rating of Buy and set a new price target of $50.00 from $45.00 previously

    11/12/24 8:15:57 AM ET
    $NUTX
    Real Estate

    Maxim Group initiated coverage on Nutex Health with a new price target

    Maxim Group initiated coverage of Nutex Health with a rating of Buy and set a new price target of $45.00

    9/18/24 8:12:45 AM ET
    $NUTX
    Real Estate

    $APDN
    $ATXI
    $IMRA
    $MRKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturnBitwise COINOption Income Strategy ETFICOI$0.6149255.74 %0.00 %100.00 %02/27/202603/03/2026-12.65 %N/A-25.29 %Bitwise MARAOption Income Strategy ETFIMRA$0.3058725.67 %0.00 %100.00 %02/27/2026

    2/26/26 4:22:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    $APDN
    $ATXI
    $IMRA
    $MRKR
    SEC Filings

    View All

    SEC Form DEF 14C filed by Sunshine Biopharma Inc.

    DEF 14C - Sunshine Biopharma Inc. (0001402328) (Filer)

    3/2/26 4:05:01 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    2/26/26 8:49:40 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)

    2/23/26 4:06:15 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $ATXI
    $IMRA
    $MRKR
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Announces Changes to Board of Directors

    MINNEAPOLIS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced the appointment of Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026. Ms. Field is the Chief Executive Officer of ISpecimen Inc., where she oversees performance improvement and the redevelopment of the proprietary software platform. Prior to serving as Chief Executive Officer she served as President, Chairman, and as an independent director. She has served as a director of LogProstyle since September 2024, as an Executive Director of Akanda Corporation since Ju

    1/23/26 4:40:27 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APDN
    $ATXI
    $IMRA
    $MRKR
    Financials

    Live finance-specific insights

    View All

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturnBitwise COINOption Income Strategy ETFICOI$0.6149255.74 %0.00 %100.00 %02/27/202603/03/2026-12.65 %N/A-25.29 %Bitwise MARAOption Income Strategy ETFIMRA$0.3058725.67 %0.00 %100.00 %02/27/2026

    2/26/26 4:22:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APDN
    $ATXI
    $IMRA
    $MRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Sunshine Biopharma Inc.

    SC 13G/A - Sunshine Biopharma Inc. (0001402328) (Subject)

    11/14/24 4:28:14 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care